thalidomide has been researched along with incb-018424 in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Barosi, G; Rosti, V | 1 |
| Santos, FP; Verstovsek, S | 1 |
| Cervantes, F; Martinez-Trillos, A | 1 |
| Andrei, M; Sindhu, H; Wang, JC | 1 |
| Birgegård, G | 1 |
| Miyamoto, T; Yoshimoto, G | 1 |
| Borthakur, G; Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wang, X; Zhou, L | 1 |
| Aylı, M; Cengiz Seval, G; Özcan, M | 1 |
| Bhalla, KN; Coarfa, C; Coleman, KG; Crew, AP; Crews, CM; DiNardo, C; Fiskus, W; Kadia, TM; Kim, MS; Manshouri, T; Mill, CP; Nowak, AJ; Pemmaraju, N; Qian, Y; Qiu, P; Raina, K; Rajapakshe, K; Saenz, DT; Shen, A; Sun, B; Verstovsek, S | 1 |
| Braga, WMT; Colleoni, GWB; Davies, FE; de Carvalho, MF; de Oliveira, MB; Eugenio, AIP; Fernando, RC; Fook-Alves, VL; Sanson, LFG | 1 |
| Al Ali, N; Komrokji, RS; Kuykendall, AT; Lancet, JE; List, AF; Padron, E; Sallman, DA; Sweet, K; Talati, C; Zuckerman, KS | 1 |
| Cardwell, LA; Cline, A; Feldman, SR | 1 |
| Cameron, H; Drennan, AC; Kellicut, A; Kelm, A; Kimpara, S; Li, Y; Lu, L; Rui, L; Rumball, I; Selzer, C; Waldmann, TA; Wang, F; Zhang, M; Zhu, F | 1 |
| Chen, J; Gale, RP; Li, B; Pan, L; Qin, T; Qu, S; Wu, J; Xiao, Z; Xu, Z; Yan, X; Zhang, P; Zhang, Y | 1 |
6 review(s) available for thalidomide and incb-018424
| Article | Year |
|---|---|
Novel strategies for patients with chronic myeloproliferative disorders.
Topics: Chronic Disease; Humans; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quinolones; Recombinant Proteins; Thalidomide | 2009 |
Breakthroughs in myeloproliferative neoplasms.
Topics: Animals; Everolimus; Humans; Immunologic Factors; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Sirolimus; Thalidomide | 2012 |
Myelofibrosis: an update on current pharmacotherapy and future directions.
Topics: Age Factors; Androgens; Anemia; Humans; Immunologic Factors; Janus Kinase 2; Mutation; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Radiotherapy; Splenomegaly; Stem Cell Transplantation; Thalidomide | 2013 |
Does anything work for anaemia in myelofibrosis?
Topics: Androgens; Anemia; Blood Transfusion; Erythropoietin; Hematinics; Humans; Immunosuppressive Agents; Interferons; Lenalidomide; Nitriles; Oxymetholone; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Thalidomide | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential | 2014 |
Advances in treating psoriasis in the elderly with small molecule inhibitors.
Topics: Adamantane; Azetidines; Clinical Trials as Topic; Humans; Niacinamide; Nitriles; Phosphodiesterase 4 Inhibitors; Piperidines; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Severity of Illness Index; Small Molecule Libraries; Sulfonamides; Thalidomide | 2017 |
1 trial(s) available for thalidomide and incb-018424
| Article | Year |
|---|---|
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Treatment Outcome | 2015 |
7 other study(ies) available for thalidomide and incb-018424
| Article | Year |
|---|---|
Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Humans; Leukocyte Count; Male; Nitriles; Platelet Count; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quality of Life; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hydroxyurea; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Male; Nitriles; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Splenectomy; Splenic Infarction; Thalidomide | 2015 |
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Topics: Animals; Antigens, CD34; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Humans; Leukemia; Leukemia, Myeloid, Acute; Mice; Myeloproliferative Disorders; Nitriles; Nuclear Proteins; Proteolysis; Pyrazoles; Pyrimidines; Thalidomide; Transcription Factors; Tumor Burden; Ubiquitin-Protein Ligases | 2017 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Stromal Cells; Thalidomide; Time Factors | 2017 |
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
Topics: Aged; Drug Approval; Drug Therapy; Female; Hematinics; Humans; Immunosuppressive Agents; Male; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Retrospective Studies; Thalidomide | 2017 |
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Immunologic Factors; Interferon Type I; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2018 |
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study.
Topics: Anemia; Danazol; Hemoglobins; Humans; Myeloproliferative Disorders; Nitriles; Pilot Projects; Prednisone; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Thrombocytopenia; Transaminases; Treatment Outcome | 2022 |